MaxCyte, Inc.

NasdaqGS:MXCT Stock Report

Market Cap: US$358.2m

MaxCyte Future Growth

Future criteria checks 2/6

MaxCyte is forecast to grow earnings and revenue by 3.3% and 20.5% per annum respectively. EPS is expected to grow by 3.8% per annum. Return on equity is forecast to be -14.5% in 3 years.

Key information

3.3%

Earnings growth rate

3.8%

EPS growth rate

Life Sciences earnings growth18.3%
Revenue growth rate20.5%
Future return on equity-14.5%
Analyst coverage

Good

Last updated12 Nov 2024

Recent future growth updates

Recent updates

MaxCyte expands capacity by relocating to new HQ in Maryland

Sep 21

MaxCyte signs strategic platform with LG Chem

Jul 12

MaxCyte: Enabling Next-Generation Cell Based Therapies, Attractive Risk-Return Profile

Sep 06

Earnings and Revenue Growth Forecasts

NasdaqGS:MXCT - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202660-33-45N/A5
12/31/202546-41-50N/A8
12/31/202438-43-52N/A7
9/30/202446-36-21-19N/A
6/30/202445-35-25-23N/A
3/31/202444-37-31-28N/A
12/31/202341-38-25-22N/A
9/30/202338-37-34-29N/A
6/30/202341-33-34-26N/A
3/31/202341-30-29-15N/A
12/31/202244-24-33-15N/A
9/30/202242-24-27-10N/A
6/30/202241-20-20-4N/A
3/31/202239-16-19-10N/A
12/31/202134-19-15-11N/A
9/30/202132-17-15-12N/A
6/30/202129-17-14-12N/A
3/31/202127-16-10-8N/A
12/31/202026-12-11-9N/A
9/30/202024-11-10-8N/A
6/30/202024-9-10-8N/A
3/31/202023-11-13-11N/A
12/31/201922-13-10-9N/A
9/30/201920-13-11-10N/A
6/30/201918-14-11-10N/A
3/31/201917-11-11-10N/A
12/31/201817-9-11-10N/A
9/30/201816-10-11-11N/A
6/30/201815-10N/A-11N/A
3/31/201814-10N/A-10N/A
12/31/201714-10N/A-10N/A
9/30/201713-8N/A-8N/A
6/30/201713-6N/A-6N/A
3/31/201713-5N/A-4N/A
12/31/201612-4N/A-2N/A
9/30/201611-4N/A-2N/A
6/30/201611-3N/A-2N/A
3/31/201610-3N/A-1N/A
12/31/20159-4N/A0N/A
9/30/20159-4N/A0N/A
6/30/20158-4N/A0N/A
3/31/20158-4N/A-1N/A
12/31/20147-4N/A-2N/A
12/31/20137-3N/A-1N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MXCT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MXCT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MXCT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MXCT's revenue (20.5% per year) is forecast to grow faster than the US market (9% per year).

High Growth Revenue: MXCT's revenue (20.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: MXCT is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y